News Articles for Vince Ippolito

Shares in Botanix have dropped more than 40 per cent after the West Perth biotech announced a $45 million capital raising, but at a significant discount to its last traded price.

Vince Ippolito-chaired Botanix will ask investors for $40 million as it eyes an expansion of its US offerings following a successful first few months in the market.

Leederville-based medical dermatology company Botanix has announced it will tap investors for $70 million to fund the launch of its recently US Food and Drug Administration approved Sofdra gel.

Clinical dermatology company Botanix Pharmaceuticals is tapping investors for $13.5 million to help fund the commercial launch of its lead treatment.

Botanix Pharmaceuticals has secured commitments from investors and is on track to raise $12.5 million via a placement to fund the buyout of financial obligations owed to another company.

Botanix Pharmaceuticals has secured commitments from investors to raise $10 million through a placement to develop its leading product.

Business News's in-depth remuneration survey shines a light on the state's high-income earners.

Shares in Bentley-based medical cannabis company Botanix Pharmaceuticals have nearly halved, after it released the results of its clinical trial for acne treatment.

Botanix Pharmaceuticals is set to raise $40 million via a share placement, less than two months after it released studies suggesting its cannabis compound could be used as an antimicrobial to mitigate superbugs.

This weekly board moves wrap includes Vince Ippolito, Stewart Washer, Matthew Madden, Jason Stirbinskis, Rob McDonald, Evan Cranston, Tolga Kumova, Dror Nagel, Leigh Junk, Maggie Niewidok, Justin Mouchacca, Laurie Marsland, Michael Hardy, Matthew Carr, Cameron Henry, Robert Sckalor, and David McArthur.

Our daily board moves wrap includes Michael Konnert, Vince Ippolito, Patrick Holywell, Anthony Mankarios, Keith Smith, Travis McKenzie, Tim Wilson, and XiaoHua Liu.

Botanix Pharmaceuticals has appointed Vince Ippolito as its president in the US, and subject to shareholder approval, he will also assume the role of executive chairman for the company.